MARKET

XENE

XENE

Xenon Pharmaceut
NASDAQ
49.46
+0.21
+0.43%
After Hours: 49.46 0 0.00% 16:00 02/23 EST
OPEN
49.21
PREV CLOSE
49.25
HIGH
49.51
LOW
48.74
VOLUME
296.36K
TURNOVER
0
52 WEEK HIGH
50.98
52 WEEK LOW
27.99
MARKET CAP
3.72B
P/E (TTM)
-18.6010
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at XENE last week (0212-0216)?
Weekly Report · 02/19 10:34
This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space
RBC Capital Markets has initiated Biohaven Ltd (NYSE:BHVN) with an Outperform rating and a price target of $62. RBC Capital says the lead asset Kv7-7000 holds exceptional potential in treating epilepsy and mood disorders. The company's shares are up 1.28% on Friday.
Benzinga · 02/16 18:58
Xenon Pharmaceut: [Amend]Statement of acquisition of beneficial ownership by individuals
Press release · 02/14 21:13
Weekly Report: what happened at XENE last week (0205-0209)?
Weekly Report · 02/12 10:27
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Disc Medicine (IRON) and Renalytix AI (RNLX)
TipRanks · 02/09 13:31
Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks'
Seeking Alpha · 02/08 21:30
Weekly Report: what happened at XENE last week (0129-0202)?
Weekly Report · 02/05 10:32
Weekly Report: what happened at XENE last week (0122-0126)?
Weekly Report · 01/29 10:26
More
About XENE
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).

Webull offers Xenon Pharmaceuticals Inc stock information, including NASDAQ: XENE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XENE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XENE stock methods without spending real money on the virtual paper trading platform.